Avenue Therapeutics, Inc. (NASDAQ:ATXI – Get Free Report) shares shot up 4.7% during mid-day trading on Tuesday . The stock traded as high as $0.5382 and last traded at $0.50. Approximately 4,912 shares were traded during mid-day trading, a decline of 28% from the average session volume of 6,836 shares. The stock had previously closed at $0.4776.
Avenue Therapeutics Stock Up 4.7%
The company has a market capitalization of $1.65 million, a P/E ratio of 0.03 and a beta of -0.18. The business has a fifty day moving average price of $0.40 and a 200 day moving average price of $0.37.
Avenue Therapeutics Company Profile
Avenue Therapeutics, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for acute pain and other central nervous system conditions. The company is a subsidiary of Fortress Biotech, Inc and has historically concentrated its efforts on hospital-based treatments that address unmet medical needs.
Avenue’s lead product candidate is an intravenous formulation of tramadol intended to manage acute postoperative pain in adults who require an opioid analgesic.
Further Reading
- Five stocks we like better than Avenue Therapeutics
- Meta’s Muse Highlights Arm’s Growing Role in AI Infrastructure
- Oura’s $15.6 Billion IPO Is Betting Investors See More Than a Smart Ring
- AMD Chips Away at NVIDIA’s AI Throne
- Is the Fed Playing Chess With Rates—Or Just Behind the Curve Again?
Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
